| Patient | Jack London |
|---|---|
| Date of birth | 1987-01-12 |
| Identifiers | MRN HR-ET010-SYN; SSN (made up) 000-10-4482 |
| Document date | 2026-08-18 |
| Author | Eleanor Whitcombe-Ibe, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Two-week review after stopping alcohol and starting losartan, seen the same day by nephrology. [S]
Mr. London stopped drinking on the morning after his intake visit and took the five-day chlordiazepoxide taper as prescribed, with a daily telephone check from the nurse. The first three days brought sweats, a tremor and poor sleep, at worst a CIWA-Ar of 11 on the second day, with no hallucinations or seizures; by the fifth day the tremor had gone, and he has had no alcohol since. He missed two mornings of writing and has written his thousand words every other day. He has taken losartan 50 mg daily without dizziness and stopped naproxen; acetaminophen eases his knee. His ankles are less swollen. He has seen the clinic's addiction counselor once. The insurance examination report has arrived, confirming a creatinine of 1.7 mg/dL about fourteen months ago. Ultrasound and liver elastography were done this morning. He sees Dr. Mbatha-Rasmussen of nephrology this afternoon. [S]
| Element | Detail |
|---|---|
| Alcohol | None for twelve days; withdrawal completed, peak CIWA-Ar 11 |
| Losartan | 50 mg daily for two weeks; no side effects |
| Potassium and creatinine | 4.9 mmol/L; 2.04 mg/dL (eGFR 42), up 3 percent |
| Earlier creatinine | 1.7 mg/dL about fourteen months ago |
| Ultrasound | Kidneys normal in size, echogenic, no stones or obstruction; fatty liver |
| Elastography | Liver stiffness 7.2 kPa |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired, but sleeping better than last week |
| Cardiovascular | Positive | Ankle swelling less |
| Genitourinary | Negative | No flank pain or blood in the urine |
| Neurological | Negative | Tremor gone; no confusion |
| Psychiatric | Positive | Restless and irritable; no thoughts of self-harm |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Naproxen 500 mg oral tablet twice daily, bought over the counter at full strength and taken most days for about two years for knee and back pain; stopped at intake | One tablet by mouth twice a day, self-directed | Oral route | 2024-08-01 to 2026-08-04 | stopped | S |
| Losartan 50 mg oral tablet once daily | One tablet by mouth every morning | Oral route | 2026-08-04 to 2026-09-15 | completed | S |
| Chlordiazepoxide 25 mg oral capsule, fixed five-day taper for alcohol withdrawal (four capsules on day 1, three on day 2, two on day 3, one on days 4 and 5), dispensed for five days only, with a daily telephone check | Up to one capsule four times a day on day 1, tapering to one a day by day 4; stop after day 5; no alcohol or driving | Oral route | 2026-08-04 to 2026-08-08 | completed | S |
| Thiamine 100 mg oral tablet once daily | One tablet by mouth daily | Oral route | 2026-08-04 | active | S |
| Acetaminophen 500 mg oral tablet, one or two tablets up to four times a day as needed for pain, no more than 2,000 mg in a day, in place of naproxen | One to two tablets by mouth every six hours as needed; no more than four tablets a day | Oral route | 2026-08-04 | active | S |
| Naltrexone 50 mg oral tablet once daily, with a wallet card warning that it blocks opioid pain medicines | One tablet by mouth every morning | Oral route | 2026-08-18 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-08-18 | Body height | 173 | cm | S |
| 2026-08-18 | Body weight | 83.6 | kg | S |
| 2026-08-18 | Body mass index (BMI) [Ratio] | 27.9 | kg/m2 | S |
| 2026-08-18 | Systolic blood pressure | 146 | mm[Hg] | S |
| 2026-08-18 | Diastolic blood pressure | 92 | mm[Hg] | S |
| 2026-08-18 | Heart rate | 84 | /min | S |
| 2026-08-18 | Respiratory rate | 16 | /min | S |
| 2026-08-18 | Body temperature | 36.6 | Cel | S |
| 2026-08-18 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-08-18 | Potassium [Moles/volume] in Serum or Plasma | 4.9 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-08-18 | Creatinine [Mass/volume] in Serum or Plasma | 2.04 | mg/dL | 0.74-1.35 mg/dL | High | S |
| 2026-08-18 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 42 | mL/min/{1.73_m2} | 45 to 59 is G3a; 30 to 44 is G3b | Low | S |
| 2026-08-18 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 49 | U/L | 10-40 U/L | High | S |
| 2026-08-18 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 36 | U/L | 9-46 U/L | Normal | S |
| 2026-08-18 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 141 | U/L | 8-61 U/L | High | S |
Vital signs recorded on 2026-08-18; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 146/92, pulse 84; weight 83.6 kg |
| Cardiovascular | Regular rhythm; no murmur; trace ankle edema |
| Neurological | No tremor; gait normal |
| Psychiatric | Calm and engaged; no thoughts of suicide |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Tiredness, ankle swelling and high blood pressure (158/98 mmHg) with a raised creatinine (1.98 mg/dL, eGFR 43) and albumin in the urine (240 mg/g), found at intake; a creatinine of 1.7 mg/dL at an insurance examination about fourteen months ago, by his account; chronicity and cause under evaluation with a nephrology consultation | resolved | confirmed | R94.4 | S — Synthetic presenting problem anchored to the documented kidney damage found in 1913; superseded when the consultation staged chronic kidney disease. |
| Chronic kidney disease, stage G3b A2 (eGFR 42 to 43, urine albumin 240 mg/g), most likely from hypertension with a contribution from two years of daily naproxen; kidneys of normal size, without stones or obstruction; urine sediment bland; synthetic modern diagnosis linked to his documented kidney disease | active | confirmed | N18.32 | S — Synthetic modern diagnosis made at the consultation, anchored to his documented kidney damage and death from uraemia; the cause in the modern episode is synthetic and is not a claim about his real kidneys. |
| Hypertensive chronic kidney disease, untreated until intake | active | confirmed | I12.9 | S — Synthetic modern diagnosis made at the consultation. |
| Alcohol use disorder, severe (seven DSM-5-TR criteria): a bottle of whisky or more most days for years, a morning drink to steady his hands, failed attempts to cut down, and drinking despite knowing it harms his health; AUDIT 27; PEth 410 ng/mL | active | confirmed | F10.20 | S — Synthetic modern diagnosis anchored to his own published account of heavy drinking; the criteria, scores and amounts are synthetic and are not a claim about his real drinking. |
| Alcohol-associated fatty liver without advanced fibrosis (liver stiffness 7.2 kPa; steatosis on ultrasound); FIB-4 2.28 at intake | active | confirmed | K70.0 | S — Synthetic finding of the ultrasound and elastography at the consultation; not a claim about his real liver. |
| Daily self-directed naproxen for knee and back pain for about two years, stopped at intake; acetaminophen in its place | resolved | confirmed | Z79.1 | S — Synthetic medication history; the joint pain is anchored to the documented rheumatism of 1914, which is not given a diagnosis. |
| Cigarette smoking, about ten a day; not ready to stop while he stops drinking | active | confirmed | F17.210 | S — Synthetic tobacco use; a physician-author's suggestion of heavy tobacco use is recorded only as a retrospective claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Standardized office blood pressure (five minutes' rest, validated device, average of readings) | Every visit | Completed today | 146/92 mmHg |
| Laboratory | Potassium and creatinine after starting or changing losartan or an SGLT2 inhibitor | Two to four weeks after each start or change | Completed today | Two weeks after losartan 50 mg: potassium 4.9 mmol/L; creatinine 2.04 mg/dL, up 3 percent; eGFR 42 |
| Laboratory | Creatinine with eGFR and urine albumin-to-creatinine ratio | G3b A2: twice a year, and at each medicine check | Up to date | eGFR 43 and urine albumin 240 mg/g at intake; with a creatinine of 1.7 mg/dL fourteen months ago, chronic for more than three months |
| Laboratory | Urinalysis with microscopy | At diagnosis | Up to date | Bland at intake: 2+ protein, no blood, casts or crystals |
| Imaging | Kidney ultrasound | At diagnosis of chronic kidney disease of unclear cause | Completed today | Kidneys 10.8 and 11.0 cm, echogenic, no stones or obstruction |
| Laboratory | Calcium, phosphate and PTH | G3a to G3b: every six to twelve months | Up to date | Calcium 9.2 and phosphate 3.8 mg/dL; PTH 74 pg/mL, mildly high, at intake |
| Laboratory | 25-hydroxyvitamin D | At baseline | Deferred | The baseline 25-hydroxyvitamin D was left off the intake order and was not drawn. PTH is only mildly high and calcium and phosphate are normal, so no harm is likely from a delay of a few weeks. Corrective action: added to the next blood draw, and the clinic's new-CKD order set checked |
| Laboratory | Hemoglobin | G3: at least yearly | Up to date | 13.6 g/dL at intake |
| Laboratory | Lipid panel | Once at diagnosis | Up to date | LDL 128 mg/dL at intake; statin not indicated at 39 |
| Survey | Kidney failure risk equation (2- and 5-year) | Yearly in G3 to G5, and before referral decisions | Completed today | Five-year risk about 5 percent; two-year about 1.5 percent |
| Medication safety | Medication reconciliation: no NSAIDs, kidney dosing, contrast safety | Every visit | Completed today | Naproxen stopped; acetaminophen within 2,000 mg a day |
| Self-management | Lifestyle: sodium below 2 g a day, activity, diet, weight | Every visit | Completed today | Sodium below 2 g a day explained; protein about 0.8 g/kg |
| Survey | Drinking since the last visit (self-report) | Every visit | Completed today | None for twelve days |
| Medication safety | Withdrawal monitoring (CIWA-Ar) and thiamine | During withdrawal; thiamine throughout early recovery | Completed today | Withdrawal completed with a peak CIWA-Ar of 11 on day 2; no seizures or hallucinations; thiamine continued |
| Laboratory | Liver tests (AST, ALT, GGT) on naltrexone | At baseline, at four to six weeks, then every few months | Completed today | Before naltrexone: AST 49, ALT 36, GGT 141 U/L, falling |
| Medication safety | Naltrexone safety: opioid use, nausea, wallet card | At the start and every visit | Completed today | No opioid use; wallet card given; started today |
| Imaging | Liver fibrosis: FIB-4, then elastography if indeterminate | At diagnosis of alcohol-associated liver disease | Completed today | FIB-4 2.28 at intake; liver stiffness 7.2 kPa today |
| Referral | Nephrology consultation | At diagnosis, with a five-year kidney failure risk of 3 to 5 percent or more | Completed today | Seen by Dr. Mbatha-Rasmussen today |
| Referral | Addiction-focused counseling and mutual help | Weekly in early recovery | Completed today | First session done; weekly from now |
| Survey | Suicide-risk review, firearms storage, safety plan and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; firearms locked with the ammunition apart; 988 card carried |
| Self-management | Tobacco use and readiness to stop | Every visit | Completed today | About ten a day; not ready to stop |
Goal progress:
Guideline basis: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension and depression monographs (2026); The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020); AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis (2025); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024)
Follow-up: Six-week review with potassium, creatinine, urine albumin, liver tests, PEth and vitamin D. Counseling weekly. The clinic or 988 at any hour. Next scheduled visit 2026-09-15: six-week review: drinking and PEth, blood pressure, potassium and creatinine, urine albumin, liver tests, mood and safety. [S]